THE GLOBAL IMMUNOGLOBULINS MARKET SIZE WAS VALUED AT USD 13.59 BILLION IN 2020 AND IS EXPECTED TO REACH USD 21.58 BILLION BY 2026, GROWING AT A CAGR OF 8.01% DURING THE FORECAST PERIOD

Global Immunoglobulins Market Size, Share, Trends Analysis Report by

  • Product: Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, & Intramuscular Immunoglobulin
  • Application: Primary Immunodeficiency, Chronic Immune Deficiency Polyradiculoneuropathy, Secondary Immunodeficiency, Immune Thrombocytopenic Purpura, Myasthenia Gravis, and Others
  • End-User: Hospital & Clinic, Homecare
  • Geography: North America, Europe, APAC, Latin America, Middle East & Africa

Industry Analysis Report Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2021–2026

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

262 Pages

icon-table

105 Tables

icon-chart

125 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

13 Companies

icon-market

4 Market Segment

GLOBAL IMMUNOGLOBULINS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE USD 21.58 Billion USD (2026)
CAGR 8.01% (2021-2026)
BASE YEAR 2020
FORECAST YEAR 2021-2026
MARKET SEGMENTS By Product (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, & Intramuscular Immunoglobulin) By Application (Primary Immunodeficiency, Chronic Immune Deficiency Polyradiculoneuropathy, Secondary Immunodeficiency, Immune Thrombocytopenic Purpura, Myasthenia Gravis, and Others), By End User (Hospital & Clinic, Homecare)
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey

MARKET INSIGHTS

Immunoglobulins Market was valued at USD 13.5 billion in 2020 and is expected to reach USD 21.58 billion by 2026, growing at a CAGR of 8.01% from 2022 to 2027. Immunoglobulins are the antibodies produced by the plasma cells, which are part of the body’s immune system. Chemically immunoglobulins are glycoprotein molecules, secreted in response to any antigen which enters in the body. The pandemic has had and continues to have a major impact on the plasma derivatives industry. It contributed to the increase in the cost/liter of collected plasma due to the increased donor fees and increased incidence of a fixed cost of centers with respect to the lower volumes collected. The recent developments and the increasing scope of immunoglobulin products in treating numerous rare and autoimmune diseases have increased the growth rate.

KEY HIGHLIGHTS

  • The price of immunoglobulin increased by around 5% in Europe and by 6% in the US.
  • With the increasing outcome of the fractionation and the challenge of plasma shortage, the technological and scientific developments in the field of plasma fractionation are expected to drive the market.
  • Immunoglobulins dominate the industry of plasma-derived products. This share is largely attributed to the increasing demand resulting from developed ways of diagnosing autoimmune diseases.
  • The major challenge for the industry is to maintain the balance between supply and demand. As the immunoglobulin products require blood plasma, the production value is limited by the quantity of plasma collected.
  • Partnerships with the official plasma collection agencies of the country have propelled the growth of many vendors.

SEGMENTATION ANALYSIS

  • Intravenous immunoglobulins (IVIG) are the most used form, to manage autoimmune diseases and immunodeficiency. Since the proposed therapeutic use of immunoglobulins, it is being administered through the intravenous route, which provides maximum bioavailability and maximum efficacy.
  • The market is led by primary immunodeficiency, which acquired 26.05% of the global immunoglobulins market in 2020. The symptoms of primary immunodeficiencies are frequent pneumonia, baronial infections, sinus infection, skin infections, meningitis, inflammation, low platelet count, etc.
  • The largest immunoglobulins market share based on end-users is acquired by the hospital and clinic segment. The home care segment is expected to grow faster because of the increasing demand for home healthcare services.

GEOGRAPHICAL ANALYSIS

  • North America acquired a 46.00% share of the global immunoglobulins market in 2020. This is attributed to many factors such as higher awareness of personal health, a patient-centric healthcare system, advancements in healthcare, higher throughput of plasma collection centers, leading global vendors being native to the industry, etc.
  • Europe is the second-largest market for immunoglobulin products because of its higher demand compared to other regions. The region has a higher awareness and highly regulated market, which enables safe blood and plasma collection practices.
  • APAC is considered an emerging industry for immunoglobulin products, which are needed for treating autoimmune disorders. China is leading the APAC immunoglobulins market. The Chinese population has a higher awareness of blood donation and its possible use in manufacturing life-saving products.

VENDOR ANALYSIS

  • The key players in the industry are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG.
  • The industry is dominated by mainly three vendors, CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A. They share a highly competitive environment, where each competes in terms of newer product launches and regulatory approval for those and existing products.
  • For new vendors, emerging markets and low-resource countries are ideal markets, as they have a higher population and greater inclination towards donating blood or plasma in compensation.
  • For the vendors in the industry, it is crucial to procure the plasma for fractionation. It can be done through wide installations of plasma collection centers across the countries, allowing the collection of higher volumes of plasma.
  • Partnerships with the official plasma collection agencies of the country have propelled the growth of many vendors. Many new vendors have benefitted from such partnerships.

The global immunoglobulins market research report includes an in-depth analysis of the industry analysis with market dynamics, competitive landscape, drivers, and restraints for the following segments

By Product

  • Intravenous Type
  • Subcutaneous Type
  • Intramuscular Type

By Application

  • Primary Immunodeficiency
  • Chronic Immune Deficiency Polyradiculoneuropathy
  • Secondary Immunodeficiency
  • Immune Thrombocytopenic Purpura
  • Myasthenia Gravis
  • Others

By End User

  • Hospital & Clinic
  • Homecare

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Frequently Asked Questions

How Big is the Immunoglobulins Market?

The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is expected to reach USD 21.58 billion by 2026.

What are the key trends in the Immunoglobulins Market?

The key trends are developments in the plasma Fractionation Process, immunoglobulins in homecare, and recent regulatory approvals for immunoglobulin.

Which region accounted for the largest Immunoglobulins Market Share?

North America region accounted for the largest Immunoglobulins Market share.

Who are the key players in the immunoglobulins market?

The key players are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG

What are the factors driving the immunoglobulins market?

The factors driving the immunoglobulins market are the impact of the use of IVIg during transplant and self-sufficiency programs for plasma-derived medicinal products.

Download Free Sample

The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is expected to reach USD 21.58 billion by 2026, growing at a CAGR of 8.01% during the forecast period.

The following factors are likely to contribute to the growth of the immunoglobulins market during the forecast period:

  • impact of the use of IVIg during transplant
  • self-sufficiency programs for plasma-derived medicinal products
  • Fractionation Process, and immunoglobulins in homecare
  • Recent regulatory approvals for immunoglobulin.

Base Year:  2020

Forecast Year:  2021–2026

The study considers the immunoglobulins market present scenario and it's market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Major Vendors

  • Takeda Pharmaceutical Company Limited
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • CSL Limited
  • Grifols, S.A
  • Kendrion Biopharma
  • Octapharma AG.

Other Prominent Vendors

  • China Biologic Products Holding, Inc.
    • Business Overview
    • Product Offerings
  • Biotest AG
  • LFB S.A.
  • ADMA Biologics, Inc.
  • Omrix Biopharmaceuticals LTD
  • Zydus Cadila
  • Bharat Serums And Vaccines Limited
  • Reliance Life Sciences

Segmentation By Product

  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
  • Intramuscular Immunoglobulin

Segmentation By Application

  • Primary Immunodeficiency
  • Chronic Immune Deficiency Polyradiculoneuropathy
  • Secondary Immunodeficiency
  • Immune Thrombocytopenic Purpura
  • Myasthenia Gravis
  • Others

By End User

  • Hospital & Clinic
  • Homecare

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY PRODUCT TYPE

4.3.2 MARKET SEGMENTATION BY APPLICATION

4.3.3 MARKET SEGMENTATION BY END-USER

4.3.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

7.2 COVID-19 IMPACT ON PLASMA THERAPIES

8 MARKET OPPORTUNITIES & TRENDS

8.1 DEVELOPMENTS IN PLASMA FRACTIONATION PROCESS

8.2 IMMUNOGLOBULINS IN HOMECARE

9 MARKET GROWTH ENABLERS

9.1 RECENT REGULATORY APPROVALS FOR IMMUNOGLOBULINS

9.2 USE OF IVIG DURING TRANSPLANT

9.3 SELF-SUFFICIENCY PROGRAMS FOR PLASMA-DERIVED MEDICINAL PRODUCTS

10 MARKET GROWTH RESTRAINTS

10.1 IVIG-ASSOCIATED HEMOLYSIS

10.2 SHORTAGE OF IMMUNOGLOBULIN PRODUCTS

11 MARKET LANDSCAPE

11.1 MARKET OVERVIEW

11.2 MARKET SIZE & FORECAST

11.2.1 PRODUCT TYPE INSIGHTS

11.2.2 APPLICATION INSIGHTS

11.2.3 END-USER INSIGHTS

11.2.4 GEOGRAPHIC INSIGHTS

11.3 FIVE FORCES ANALYSIS

11.3.1 THREAT OF NEW ENTRANTS

11.3.2 BARGAINING POWER OF SUPPLIERS

11.3.3 BARGAINING POWER OF BUYERS

11.3.4 THREAT OF SUBSTITUTES

11.3.5 COMPETITIVE RIVALRY

12 PRODUCT

12.1 MARKET SNAPSHOT & GROWTH ENGINE

12.2 MARKET OVERVIEW

12.3 INTRAVENOUS IMMUNOGLOBULINS

12.3.1 MARKET OVERVIEW

12.3.2 MARKET SIZE & FORECAST

12.3.3 INTRAVENOUS IMMUNOGLOBULINS: GEOGRAPHICAL SEGMENTATION

12.4 SUBCUTANEOUS IMMUNOGLOBULINS

12.4.1 MARKET OVERVIEW

12.4.2 MARKET SIZE & FORECAST

12.4.3 SUBCUTANEOUS IMMUNOGLOBULINS: GEOGRAPHICAL SEGMENTATION

12.5 INTRAMUSCULAR IMMUNOGLOBULINS

12.5.1 MARKET OVERVIEW

12.5.2 MARKET SIZE & FORECAST

12.5.3 INTRAMUSCULAR IMMUNOGLOBULINS: GEOGRAPHICAL SEGMENTATION

13 APPLICATION

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 PRIMARY IMMUNODEFICIENCY

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 PRIMARY IMMUNODEFICIENCY: GEOGRAPHY SEGMENTATION

13.4 CHRONIC IMMUNE DEFICIENCY POLYRADICULONEUROPATHY

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 CHRONIC IMMUNE DEFICIENCY POLYRADICULONEUROPATHY: GEOGRAPHY SEGMENTATION

13.5 SECONDARY IMMUNODEFICIENCY

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

13.5.3 SECONDARY IMMUNODEFICIENCY: GEOGRAPHY SEGMENTATION

13.6 IMMUNE THROMBOCYTOPENIC PURPURA

13.6.1 MARKET OVERVIEW

13.6.2 MARKET SIZE & FORECAST

13.6.3 IMMUNE THROMBOCYTOPENIC PURPURA: GEOGRAPHY SEGMENTATION

13.7 MYASTHENIA GRAVIS

13.7.1 MARKET OVERVIEW

13.7.2 MARKET SIZE & FORECAST

13.7.3 MYASTHENIA GRAVIS: GEOGRAPHY SEGMENTATION

13.8 OTHERS

13.8.1 MARKET OVERVIEW

13.8.2 MARKET SIZE & FORECAST

13.8.3 OTHERS: GEOGRAPHICAL SEGMENTATION

14 END-USER

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 HOSPITALS & CLINICS

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 HOSPITALS & CLINICS: GEOGRAPHY SEGMENTATION

14.4 HOMECARE

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 HOMECARE: GEOGRAPHY SEGMENTATION

15 GEOGRAPHY

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 GEOGRAPHIC OVERVIEW

16 NORTH AMERICA

16.1 MARKET OVERVIEW

16.2 MARKET SIZE & FORECAST

16.2.1 NORTH AMERICA: PRODUCT TYPE SEGMENTATION

16.2.2 NORTH AMERICA: APPLICATION SEGMENTATION

16.2.3 NORTH AMERICA: END-USER SEGMENTATION

16.3 KEY COUNTRIES

16.3.1 US: MARKET SIZE & FORECAST

16.3.2 CANADA: MARKET SIZE & FORECAST

17 EUROPE

17.1 MARKET OVERVIEW

17.2 MARKET SIZE & FORECAST

17.2.1 EUROPE: PRODUCT TYPE SEGMENTATION

17.2.2 EUROPE: APPLICATION SEGMENTATION

17.2.3 EUROPE: END-USER SEGMENTATION

17.3 KEY COUNTRIES

17.3.1 GERMANY: MARKET SIZE & FORECAST

17.3.2 FRANCE: MARKET SIZE & FORECAST

17.3.3 UK: MARKET SIZE & FORECAST

17.3.4 ITALY: MARKET SIZE & FORECAST

17.3.5 SPAIN: MARKET SIZE & FORECAST

18 APAC

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.2.1 APAC: PRODUCT TYPE SEGMENTATION

18.2.2 APAC: APPLICATION SEGMENTATION

18.2.3 APAC: END-USER SEGMENTATION

18.3 KEY COUNTRIES

18.3.1 CHINA: MARKET SIZE & FORECAST

18.3.2 JAPAN: MARKET SIZE & FORECAST

18.3.3 INDIA: MARKET SIZE & FORECAST

18.3.4 AUSTRALIA: MARKET SIZE & FORECAST

18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST

19 LATIN AMERICA

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.2.1 LATIN AMERICA: PRODUCT TYPE SEGMENTATION

19.2.2 LATIN AMERICA: APPLICATION SEGMENTATION

19.2.3 LATIN AMERICA: END-USER SEGMENTATION

19.3 KEY COUNTRIES

19.3.1 BRAZIL: MARKET SIZE & FORECAST

19.3.2 MEXICO: MARKET SIZE & FORECAST

19.3.3 ARGENTINA: MARKET SIZE & FORECAST

20 MIDDLE EAST & AFRICA

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.2.1 MIDDLE EAST & AFRICA: PRODUCT TYPE SEGMENTATION

20.2.2 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION

20.2.3 MIDDLE EAST & AFRICA: END-USER SEGMENTATION

20.3 KEY COUNTRIES

20.3.1 SOUTH AFRICA: MARKET SIZE & FORECAST

20.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST

20.3.3 TURKEY: MARKET SIZE & FORECAST

21 COMPETITIVE LANDSCAPE

21.1 COMPETITION OVERVIEW

21.2 MARKET SHARE ANALYSIS

21.2.1 CSL LIMITED

21.2.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.2.3 GRIFOLS S.A.

22 KEY COMPANY PROFILES

22.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED

22.1.1 BUSINESS OVERVIEW

22.1.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED IN IMMUNOGLOBULINS MARKET

22.1.3 PRODUCT OFFERINGS

22.1.4 KEY STRATEGIES

22.1.5 KEY STRENGTHS

22.1.6 KEY OPPORTUNITIES

22.2 CSL LIMITED

22.2.1 BUSINESS OVERVIEW

22.2.2 CSL IN IMMUNOGLOBULINS MARKET

22.2.3 PRODUCT OFFERINGS

22.2.4 KEY STRATEGIES

22.2.5 KEY STRENGTHS

22.2.6 KEY OPPORTUNITIES

22.3 GRIFOLS, S.A.

22.3.1 BUSINESS OVERVIEW

22.3.2 GRIFOLS, S.A. IN IMMUNOGLOBULINS MARKET

22.3.3 PRODUCT OFFERINGS

22.3.4 KEY STRATEGIES

22.3.5 KEY STRENGTHS

22.3.6 KEY OPPORTUNITIES

22.4 KENDRION BIOPHARMA

22.4.1 BUSINESS OVERVIEW

22.4.2 KENDRION IN IMMUNOGLOBULINS MARKET

22.4.3 PRODUCT OFFERINGS

22.4.4 KEY STRATEGIES

22.4.5 KEY STRENGTHS

22.4.6 KEY OPPORTUNITIES

22.5 OCTAPHARMA AG

22.5.1 BUSINESS OVERVIEW

22.5.2 OCTAPHARMA AG IN IMMUNOGLOBULINS MARKET

22.5.3 PRODUCT OFFERINGS

22.5.4 KEY STRATEGIES

22.5.5 KEY STRENGTHS

22.5.6 KEY OPPORTUNITIES

23 OTHER PROMINENT VENDORS

23.1 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.

23.1.1 BUSINESS OVERVIEW

23.1.2 PRODUCT OFFERINGS

23.2 BIOTEST AG

23.2.1 BUSINESS OVERVIEW

23.2.2 PRODUCT OFFERINGS

23.3 LFB S.A.

23.3.1 BUSINESS OVERVIEW

23.3.2 PRODUCT OFFERINGS

23.4 ADMA BIOLOGICS, INC.

23.4.1 BUSINESS OVERVIEW

23.4.2 PRODUCT OFFERINGS

23.5 OMRIX BIOPHARMACEUTICALS LTD

23.5.1 BUSINESS OVERVIEW

23.5.2 PRODUCT OFFERINGS

23.6 ZYDUS CADILA

23.6.1 BUSINESS OVERVIEW

23.6.2 PRODUCT OFFERINGS

23.7 BHARAT SERUMS AND VACCINES LIMITED

23.7.1 BUSINESS OVERVIEW

23.7.2 PRODUCT OFFERINGS

23.8 RELIANCE LIFE SCIENCES

23.8.1 BUSINESS OVERVIEW

23.8.2 PRODUCT OFFERINGS

24 REPORT SUMMARY

24.1 KEY TAKEAWAYS

24.2 STRATEGIC RECOMMENDATIONS

25 QUANTITATIVE SUMMARY

25.1 MARKET BY PRODUCT TYPE

25.1.1 NORTH AMERICA: PRODUCT TYPE SEGMENTATION

25.1.2 EUROPE: PRODUCT TYPE SEGMENTATION

25.1.3 APAC: PRODUCT TYPE SEGMENTATION

25.1.4 LATIN AMERICA: PRODUCT TYPE SEGMENTATION

25.1.5 MIDDLE EAST & AFRICA: PRODUCT TYPE SEGMENTATION

25.2 MARKET BY APPLICATION

25.2.1 NORTH AMERICA: APPLICATION SEGMENTATION

25.2.2 EUROPE: APPLICATION SEGMENTATION

25.2.3 APAC: APPLICATION SEGMENTATION

25.2.4 LATIN AMERICA: APPLICATION SEGMENTATION

25.2.5 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION

25.3 MARKET BY END-USER

25.3.1 NORTH AMERICA: END-USER SEGMENTATION

25.3.2 EUROPE: MARKET SIZE & FORECAST

25.3.3 APAC: MARKET SIZE & FORECAST

25.3.4 LATIN AMERICA: MARKET SIZE & FORECAST

25.3.5 MIDDLE EAST & AFRICA: MARKET SIZE & FORECAST

25.4 MARKET BY GEOGRAPHY

25.4.1 INTRAVENOUS IMMUNOGLOBULIN: GEOGRAPHY SEGMENTATION

25.4.2 SUBCUTANEOUS IMMUNOGLOBULINS: GEOGRAPHY SEGMENTATION

25.4.3 INTRAMUSCULAR IMMUNOGLOBULINS: GEOGRAPHY SEGMENTATION

25.4.4 PRIMARY IMMUNODEFICIENCY: GEOGRAPHY SEGMENTATION

25.4.5 CHRONIC IMMUNE DEFICIENCY POLYRADICULONEUROPATHY: GEOGRAPHY SEGMENTATION

25.4.6 SECONDARY IMMUNODEFICIENCY: GEOGRAPHY SEGMENTATION

25.4.7 IMMUNE THROMBOCYTOPENIC PURPURA: GEOGRAPHY SEGMENTATION

25.4.8 MYASTHENIA GRAVIS: GEOGRAPHY SEGMENTATION

25.4.9 OTHERS: GEOGRAPHY SEGMENTATION

25.4.10 HOSPITALS & CLINICS: GEOGRAPHY SEGMENTATION

25.4.11 HOMECARE: GEOGRAPHY SEGMENTATION

26 APPENDIX

26.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF GLOBAL IMMUNOGLOBULINS MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2020

EXHIBIT 3 IMPACT OF DEVELOPMENTS IN PLASMA FRACTIONATION PROCESS

EXHIBIT 4 IMPACT OF IMMUNOGLOBULINS IN HOMECARE

EXHIBIT 5 IMPACT OF RECENT REGULATORY APPROVALS FOR IMMUNOGLOBULIN

EXHIBIT 6 IMPACT OF USE OF IVIG DURING TRANSPLANT

EXHIBIT 7 SELF-SUFFICIENCY PROGRAMS FOR PLASMA-DERIVED MEDICINAL PRODUCTS

EXHIBIT 8 IMPACT OF IVIG-ASSOCIATED HEMOLYSIS

EXHIBIT 9 IMPACT OF SHORTAGE OF IMMUNOGLOBULIN PRODUCTS

EXHIBIT 10 GLOBAL IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 11 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE

EXHIBIT 12 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION

EXHIBIT 13 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER

EXHIBIT 14 GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY

EXHIBIT 15 FIVE FORCES ANALYSIS 2020

EXHIBIT 16 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 17 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE

EXHIBIT 18 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE: INCREMENTAL GROWTH 2020–2026 ($ BILLION)

EXHIBIT 19 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE: ABSOLUTE GROWTH 2020–2026 (%)

EXHIBIT 20 GLOBAL INTRAVENOUS IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 21 GLOBAL INTRAVENOUS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 22 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 23 GLOBAL SUBCUTANEOUS IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 24 GLOBAL SUBCUTANEOUS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 25 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 26 GLOBAL INTRAMUSCULAR IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 27 GLOBAL INTRAMUSCULAR IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 28 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 29 INCREMENTAL GROWTH BY SEGMENT 2020 & 2026

EXHIBIT 30 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION

EXHIBIT 31 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION: INCREMENTAL GROWTH 2020–2026 ($ BILLION)

EXHIBIT 32 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION: ABSOLUTE GROWTH 2020–2026 ($ BILLION)

EXHIBIT 33 GLOBAL PRIMARY IMMUNODEFICIENCY MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 34 GLOBAL PRIMARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 35 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 36 GLOBAL CIDP IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 37 GLOBAL CIDP IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 38 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 39 GLOBAL SECONDARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 40 GLOBAL SECONDARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 41 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 42 GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 43 GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 44 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 45 GLOBAL MYASTHENIA GRAVIS IMMUNOGLOBULINS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 46 GLOBAL MYASTHENIA GRAVIS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 47 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 48 GLOBAL IMMUNOGLOBULINS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 49 GLOBAL OTHER IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 50 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 51 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 52 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER

EXHIBIT 53 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER: INCREMENTAL GROWTH 2020–2026 ($ BILLION)

EXHIBIT 54 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER: ABSOLUTE GROWTH 2020–2026 (%)

EXHIBIT 55 GLOBAL HOSPITALS & CLINICS IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 56 GLOBAL HOSPITALS & CLINICS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 58 GLOBAL HOMECARE IMMUNOGLOBULINS MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 59 GLOBAL HOMECARE IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 61 INCREMENTAL GROWTH BY GEOGRAPHY 2020 & 2026

EXHIBIT 62 GLOBAL IMMUNOGLOBULINS MARKET: KEY COUNTRIES

EXHIBIT 63 GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH 2020–2026 ($ BILLION)

EXHIBIT 64 GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH 2020–2026 (%)

EXHIBIT 65 NORTH AMERICA IMMUNOGLOBULINS MARKET: KEY COUNTRIES 2020 ($ BILLION)

EXHIBIT 66 NORTH AMERICA IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 67 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 68 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 69 INCREMENTAL GROWTH BY END-USER 2020 & 2026

EXHIBIT 70 INCREMENTAL GROWTH IN NORTH AMERICA 2020 & 2026

EXHIBIT 71 IMMUNOGLOBULINS MARKET IN US 2020–2026 ($ BILLION)

EXHIBIT 72 IMMUNOGLOBULINS MARKET IN CANADA 2020–2026 ($ BILLION)

EXHIBIT 73 EUROPE IMMUNOGLOBULINS MARKET: KEY COUNTRIES 2020 ($ BILLION)

EXHIBIT 74 EUROPE IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 75 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 76 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 77 INCREMENTAL GROWTH BY END-USER 2020 & 2026

EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE 2020 & 2026

EXHIBIT 79 IMMUNOGLOBULINS MARKET IN GERMANY 2020–2026 ($ BILLION)

EXHIBIT 80 IMMUNOGLOBULINS MARKET IN FRANCE 2020–2026 ($ BILLION)

EXHIBIT 81 IMMUNOGLOBULINS MARKET IN UK 2020–2026 ($ BILLION)

EXHIBIT 82 IMMUNOGLOBULINS MARKET IN ITALY 2020–2026 ($ BILLION)

EXHIBIT 83 IMMUNOGLOBULINS MARKET IN SPAIN 2020–2026 ($ BILLION)

EXHIBIT 84 APAC IMMUNOGLOBULINS MARKET: KEY COUNTRIES 2020 ($ BILLION)

EXHIBIT 85 IMMUNOGLOBULINS MARKET IN APAC 2020–2026 ($ BILLION)

EXHIBIT 86 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 87 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 88 INCREMENTAL GROWTH BY END-USER 2020 & 2026

EXHIBIT 89 INCREMENTAL GROWTH IN APAC 2020 & 2026

EXHIBIT 90 IMMUNOGLOBULINS MARKET IN CHINA 2020–2026 ($ BILLION)

EXHIBIT 91 IMMUNOGLOBULINS MARKET IN JAPAN 2020–2026 ($ BILLION)

EXHIBIT 92 IMMUNOGLOBULINS MARKET IN INDIA 2020–2026 ($ BILLION)

EXHIBIT 93 IMMUNOGLOBULINS MARKET IN AUSTRALIA 2020–2026 ($ BILLION)

EXHIBIT 94 IMMUNOGLOBULINS MARKET IN SOUTH KOREA 2020–2026 ($ BILLION)

EXHIBIT 95 LATIN AMERICA IMMUNOGLOBULINS MARKET: KEY COUNTRIES 2020 ($ BILLION)

EXHIBIT 96 LATIN AMERICA IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 97 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 98 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 99 INCREMENTAL GROWTH BY END-USER 2020 & 2026

EXHIBIT 100 INCREMENTAL GROWTH IN LATIN AMERICA 2020 & 2026

EXHIBIT 101 IMMUNOGLOBULINS MARKET IN BRAZIL 2020–2026 ($ BILLION)

EXHIBIT 102 IMMUNOGLOBULINS MARKET IN MEXICO 2020–2026 ($ BILLION)

EXHIBIT 103 IMMUNOGLOBULINS MARKET IN ARGENTINA 2020–2026 ($ BILLION)

EXHIBIT 104 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET: KEY COUNTRIES 2020 ($ BILLION)

EXHIBIT 105 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

EXHIBIT 106 INCREMENTAL GROWTH BY PRODUCT TYPE 2020 & 2026

EXHIBIT 107 INCREMENTAL GROWTH BY APPLICATION 2020 & 2026

EXHIBIT 108 INCREMENTAL GROWTH BY END-USER 2020 & 2026

EXHIBIT 109 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2020 & 2026

EXHIBIT 110 IMMUNOGLOBULINS MARKET IN SOUTH AFRICA 2020–2026 ($ BILLION)

EXHIBIT 111 IMMUNOGLOBULINS MARKET IN SAUDI ARABIA 2020–2026 ($ BILLION)

EXHIBIT 112 IMMUNOGLOBULINS MARKET IN TURKEY 2020–2026 ($ BILLION)

EXHIBIT 113 GLOBAL IMMUNOGLOBULINS MARKET: VENDOR MARKET SHARE (2020)

EXHIBIT 114 TAKEDA PHARMACEUTICAL COMPANY LIMITED: TOTAL REVENUE 2018−2020 ($ BILLION)

EXHIBIT 115 TAKEDA PHARMACEUTICAL COMPANY LIMITED: TOTAL REVENUE BY GEOGRAPHY 2019 & 2020 ($ BILLION)

EXHIBIT 116 TAKEDA PHARMACEUTICAL COMPANY LIMITED: R&D EXPENDITURE 2018−2020 ($ BILLION)

EXHIBIT 117 TAKEDA PHARMACEUTICAL COMPANY LIMITED: TOTAL REVENUE BY IMMUNOGLOBIN 2018−2020 ($ BILLION)

EXHIBIT 118 CSL LIMITED: TOTAL REVENUE 2018−2020 ($ MILLION)

EXHIBIT 119 CSL LIMITED: R&D EXPENDITURE 2018−2020 ($ MILLION)

EXHIBIT 120 GRIFOLS, S.A.: TOTAL REVENUE 2018−2020 ($ MILLION)

EXHIBIT 121 GRIFOLS, S.A.: R&D EXPENDITURE 2018−2020 ($ MILLION)

EXHIBIT 122 KENDRION: TOTAL REVENUE 2018−2020 ($ MILLION)

EXHIBIT 123 KENDRION: R&D EXPENDITURE 2018−2020 ($ MILLION)

EXHIBIT 124 OCTAPHARMA AG: TOTAL REVENUE 2018−2020 ($ MILLION)

EXHIBIT 125 OCTAPHARMA AG: R&D EXPENDITURE 2018−2020 ($ MILLION)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2013−2020

TABLE 3 NORTH AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 4 NORTH AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 5 NORTH AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 6 NORTH AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 7 NORTH AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 8 NORTH AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 9 EUROPE IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 10 EUROPE IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 11 EUROPE IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 12 EUROPE IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 13 EUROPE IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 14 EUROPE IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 15 APAC IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 16 APAC IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 17 APAC IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 18 APAC IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 19 APAC IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 20 APAC IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 21 LATIN AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 22 LATIN AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 23 LATIN AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 24 LATIN AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 25 LATIN AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 26 LATIN AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 27 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 28 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 29 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 30 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 31 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 32 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 33 TAKEDA PHARMACEUTICAL COMPANY LIMITED: MAJOR PRODUCT OFFERINGS

TABLE 34 CSL: MAJOR PRODUCT OFFERINGS

TABLE 35 GRIFOLS, S.A.: MAJOR PRODUCT OFFERINGS

TABLE 36 KENDRION: MAJOR PRODUCT OFFERINGS

TABLE 37 OCTAPHARMA: MAJOR PRODUCT OFFERINGS

TABLE 38 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: MAJOR PRODUCT OFFERINGS

TABLE 39 BIOTEST AG: MAJOR PRODUCT OFFERINGS

TABLE 40 LFB S.A.: MAJOR PRODUCT OFFERINGS

TABLE 41 ADMA BIOLOGICS, INC.: MAJOR PRODUCT OFFERINGS

TABLE 42 OMRIX BIOPHARMACEUTICALS LTD: MAJOR PRODUCT OFFERINGS

TABLE 43 ZYDUS CADILA: MAJOR PRODUCT OFFERINGS

TABLE 44 BHARAT SERUMS AND VACCINES LIMITED: MAJOR PRODUCT OFFERINGS

TABLE 45 RELIANCE LIFE SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 46 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 47 GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 48 NORTH AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 49 NORTH AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 50 EUROPE IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 51 EUROPE IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 52 APAC IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 53 APAC IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 54 LATIN AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 55 LATIN AMERICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 56 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 ($ BILLION)

TABLE 57 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY PRODUCT TYPE 2020–2026 (%)

TABLE 58 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 59 GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 60 NORTH AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 61 NORTH AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 62 EUROPE IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 63 EUROPE IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 64 APAC IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 65 APAC IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 66 LATIN AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 ($ BILLION)

TABLE 67 LATIN AMERICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020–2026 (%)

TABLE 68 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020−2026 ($ BILLION)

TABLE 69 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY APPLICATION 2020−2026 (%)

TABLE 70 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 71 GLOBAL IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 72 NORTH AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 73 NORTH AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020−2026 (%)

TABLE 74 EUROPE IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 75 EUROPE IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 76 APAC IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 77 APAC IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 78 LATIN AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 79 LATIN AMERICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 80 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 ($ BILLION)

TABLE 81 MIDDLE EAST & AFRICA IMMUNOGLOBULINS MARKET BY END-USER 2020–2026 (%)

TABLE 82 GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY 2020–2026 ($ BILLION)

TABLE 83 GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY 2020–2026 (%)

TABLE 84 GLOBAL INTRAVENOUS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 85 GLOBAL INTRAVENOUS IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 86 GLOBAL SUBCUTANEOUS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 87 GLOBAL SUBCUTANEOUS IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 88 GLOBAL INTRAMUSCULAR IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 89 GLOBAL INTRAMUSCULAR IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 90 GLOBAL PRIMARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 91 GLOBAL PRIMARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 92 GLOBAL CIDP IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 93 GLOBAL CIDP IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 94 GLOBAL SECONDARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 95 GLOBAL SECONDARY IMMUNODEFICIENCY IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 96 GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 97 GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 98 GLOBAL MYASTHENIA GRAVIS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 99 GLOBAL MYASTHENIA GRAVIS IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 100 GLOBAL IMMUNOGLOBULINS MARKET BY OTHERS 2020–2026 ($ BILLION)

TABLE 101 GLOBAL IMMUNOGLOBULINS MARKET BY OTHERS 2020–2026 (%)

TABLE 102 GLOBAL HOSPITALS & CLINICS IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 103 GLOBAL HOSPITALS & CLINICS IMMUNOGLOBULINS MARKET 2020–2026 (%)

TABLE 104 GLOBAL HOMECARE IMMUNOGLOBULINS MARKET 2020–2026 ($ BILLION)

TABLE 105 GLOBAL HOMECARE IMMUNOGLOBULINS MARKET 2020–2026 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date